EP Patent

EP3978074B1 — Terlipressin for treating hepatorenal syndrome type 1

Assigned to Mallinckrodt Pharmaceuticals Ireland Ltd · Expires 2024-03-06 · 2y expired

What this patent protects

Patent listed against terlipressin-acetate.

Drugs covered by this patent

terlipressin-acetate (Terlipressin acetate) · Novartis Pharmaceuticals

Patent Metadata

Patent number: EP3978074B1
Jurisdiction: EP
Classification: —
Expires: 2024-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Mallinckrodt Pharmaceuticals Ireland Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.